Cystic Fibrosis

  1. What Is Cystic Fibrosis?
  2. How CF Damages the Body
  3. Newborn Screening and Diagnosis
  4. Lung Disease in Children
  5. Nutrition and Pancreatic Disease
  6. Daily CF Care Routine
  7. CFTR Modulator Therapy — The Revolution
  8. CF and Child Development
  9. Complications in Children
  10. Transition to Adult Care
  11. Prognosis and Outlook
  12. Key Research Papers
  13. Connections

What Is Cystic Fibrosis?

Cystic fibrosis (CF) is a life-limiting inherited disease caused by mutations in the CFTR gene, located on chromosome 7q31. The CFTR gene encodes a protein that functions as a chloride channel on the surface of epithelial cells lining the airways, intestines, pancreas, sweat glands, and reproductive tract. When this channel fails to work correctly, the body cannot properly regulate the flow of salt and water across cell membranes.

CF follows an autosomal recessive inheritance pattern, meaning a child must inherit two defective copies of the CFTR gene — one from each parent — to develop the disease. Parents who each carry one defective copy have a 25% chance with each pregnancy of having a child with CF. More than 2,000 distinct CFTR mutations have been identified. The most common, called ΔF508 (delta-F508 or Phe508del), accounts for approximately 70% of CF mutations worldwide and results in a misfolded protein that is degraded before reaching the cell surface.

CF affects roughly 1 in 2,500 children of European ancestry and about 1 in 17,000 African American children. Approximately 40,000 Americans are living with CF today. Once a disease of early childhood death, advances in treatment — particularly the development of CFTR modulator medications — have transformed CF into a condition where median survival now exceeds 50 years for those with eligible mutations, and projected lifespan for children born today receiving optimal care approaches near-normal.

Back to Table of Contents

How CF Damages the Body

To understand CF, picture the cells that line your airways, intestines, and other organs as working constantly to keep surfaces moist and slippery. They do this partly by pumping chloride ions out through CFTR channels, drawing water with them. When CFTR doesn't work, chloride stays inside the cells. Sodium and water follow, staying inside too. The result is thick, dehydrated, sticky mucus that builds up wherever mucus is normally produced.

In the lungs, thick mucus clogs the airways and cannot be cleared by the tiny hair-like cilia that normally sweep debris upward. Bacteria find this environment ideal for colonization. The immune system responds with chronic inflammation, releasing enzymes that damage the lung tissue itself. Over years, repeated cycles of infection and inflammation permanently scar and dilate the airways — a condition called bronchiectasis. This progressive lung damage is the leading cause of death in CF.

In the pancreas, thick secretions block the ducts that carry digestive enzymes into the small intestine. The trapped enzymes begin digesting the pancreas itself. By early childhood, about 85% of CF patients have lost most of their exocrine pancreatic function, meaning they cannot break down fats, proteins, and fat-soluble vitamins properly. This causes malabsorption, poor growth, and nutritional deficiencies.

In the sweat glands, CFTR dysfunction means chloride cannot be reabsorbed from the sweat duct, so CF patients lose abnormally large amounts of salt in their sweat. This is the basis of the sweat chloride diagnostic test and also means children with CF need extra salt, especially in hot weather or during exercise.

In the intestines, thick secretions can block the bowel. In the liver, bile duct obstruction can cause progressive liver disease. In males, the vas deferens — the tube connecting the testes to the urethra — often fails to develop entirely, leading to obstructive azoospermia and infertility.

Back to Table of Contents

Newborn Screening and Diagnosis

The United States requires CF newborn screening in all 50 states. This has transformed the disease: children diagnosed through screening before symptoms develop have better nutritional status, better lung function, and longer survival than those diagnosed after symptoms appear.

Newborn screening begins with a blood test measuring immunoreactive trypsinogen (IRT), a pancreatic enzyme precursor that is elevated in CF newborns. Babies with elevated IRT then receive CFTR DNA mutation analysis from the same dried blood spot. The specific mutations found guide treatment decisions, particularly which CFTR modulator medications will be effective.

A positive or inconclusive newborn screen leads to a sweat chloride test, the gold standard for diagnosing CF. The test uses pilocarpine iontophoresis — a mild electrical current drives the drug pilocarpine into a small patch of skin, stimulating the sweat glands in that area to produce sweat. The sweat is collected on gauze or filter paper over 30 minutes. A minimum of 75 mg of sweat must be collected for a valid result.

Sweat chloride values are interpreted as follows: below 29 mEq/L is normal; 30–59 mEq/L is intermediate (requires further evaluation); 60 mEq/L or above is positive for CF. The test must be performed at a CF Foundation accredited care center and repeated for confirmation. Sweat chloride remains reliable throughout life and can be used at any age.

CFTR mutation analysis serves a dual purpose: confirming diagnosis and classifying the mutation class (I–VI), which determines whether the patient is eligible for specific CFTR modulator therapies. Patients with two copies of the ΔF508 mutation, or one copy of ΔF508 plus certain other mutations, may qualify for the most effective modulator combinations available.

Back to Table of Contents

Lung Disease in Children

Lung disease is the most serious aspect of CF for most children. The progression follows a predictable but variable pattern. In infancy and early childhood, Staphylococcus aureus is the most common lung pathogen, colonizing the sticky airways before any obvious illness is apparent. As children grow, Pseudomonas aeruginosa becomes the dominant pathogen, particularly a distinctive mucoid (alginate-encased) strain that is very difficult to eradicate once established and is associated with faster lung function decline.

Lung function is tracked with spirometry, a breathing test that measures how much air a person can exhale forcefully in one second (FEV1) and the total amount exhaled (FVC). FEV1 percentage of predicted normal value is the key metric followed over time. A declining FEV1 trajectory signals worsening disease. Children are typically able to perform reproducible spirometry by age 5–6 years. In the pre-modulator era, FEV1 declined an average of 1–2% per year; CFTR modulators have largely halted this decline in eligible patients.

A pulmonary exacerbation is an episode of worsening respiratory symptoms — increased cough, more mucus, decreased exercise tolerance, weight loss, and falling lung function — that requires intensified treatment. Exacerbations are managed with 14–21 days of intravenous antibiotics targeting the patient's known bacterial flora, intensified airway clearance, and nutritional support. Frequent exacerbations accelerate permanent lung damage and are a major driver of disease progression. Hospitalization is common during exacerbations in childhood.

Bronchiectasis — permanent dilation and scarring of the airway walls — begins in some CF patients in early childhood and can be seen on chest CT imaging even before lung function is measurably abnormal. Hemoptysis (coughing up blood) can occur as bronchiectatic airways become friable, usually in older children and adolescents.

Daily airway clearance therapy is essential and must begin in infancy, where it is performed by parents as chest physiotherapy (percussive clapping over the chest and back in drainage positions). As children grow, they transition to devices: the high-frequency chest wall oscillation vest (worn daily, typically 20–30 minutes twice daily), the flutter valve or Aerobika oscillating PEP device, or autogenic drainage techniques. No single method is superior; adherence is what matters most.

Back to Table of Contents

Nutrition and Pancreatic Disease in Children

Adequate nutrition is not optional in CF — it is treatment. Children with CF require 110–200% of the caloric intake recommended for healthy children of the same age and size. The reasons are compounded: malabsorption from pancreatic insufficiency wastes consumed calories, chronic infection increases metabolic demand, and the work of breathing burns extra energy. Poor nutrition leads directly to poorer lung function and higher mortality.

Approximately 85% of CF patients have exocrine pancreatic insufficiency (EPI), meaning the pancreas does not produce enough digestive enzymes to break down food normally. These patients require pancreatic enzyme replacement therapy (PERT) with every meal and snack containing fat. Enzymes are given as enteric-coated microspheres (brand names Creon, Zenpep, Pancreaze) in doses calibrated to fat content of meals, typically 500–4,000 lipase units per kilogram of body weight per meal. Enzyme doses must be adjusted individually; too little causes steatorrhea (fatty, oily stools), cramping, and weight loss; too high doses rarely cause fibrosing colonopathy, a serious bowel complication.

CF patients with EPI cannot properly absorb the fat-soluble vitamins A, D, E, and K, so they require daily supplementation with CF-specific high-dose formulations. Vitamin D deficiency is nearly universal without supplementation and contributes to bone disease. Vitamin K deficiency impairs clotting.

CF-related diabetes (CFRD) is the most common CF comorbidity beyond the lungs, affecting about 20% of adolescents and 40–50% of adults with CF. CFRD develops because fibrous scarring of the pancreas from repeated inflammation destroys the insulin-producing beta cells. Unlike type 1 diabetes it is not autoimmune, and unlike type 2 it is not primarily driven by insulin resistance — it is a unique form. CFRD is associated with faster lung function decline and increased mortality, making annual oral glucose tolerance test (OGTT) screening essential starting at age 10.

Failure to thrive — inadequate weight gain and growth — must be actively prevented. CF care centers set nutritional targets: weight-for-length at or above the 50th percentile in infants, BMI at or above the 50th percentile in children and adolescents. When oral intake is insufficient, gastrostomy tube (G-tube) feeding is recommended to provide supplemental calories overnight without burdening the child's day.

Back to Table of Contents

Daily CF Care Routine

A child with CF typically spends 1–3 hours each day on treatments before CFTR modulators and about 30–60 minutes after starting modulators. Understanding what this looks like helps families plan and helps teachers and school staff provide accommodations.

Morning treatment session (approximately 30–60 minutes): The child puts on the airway clearance vest, which inflates and vibrates at high frequency to shake mucus loose from airway walls. During this time, they simultaneously inhale nebulized medications: dornase alfa (Pulmozyme), a recombinant enzyme that cleaves the DNA in mucus, making it less viscous and easier to clear — given once or twice daily; hypertonic saline 7%, which draws water into the airway surface, thinning mucus and improving clearance — given twice daily; and for patients colonized with Pseudomonas, inhaled tobramycin in alternating monthly cycles.

Enzymes with every meal and snack: Capsules are swallowed whole (infants receive the opened microspheres in applesauce) before eating. Forgetting enzymes means the meal is largely wasted nutritionally.

Oral medications: CFTR modulators (typically one or two tablets or granules in food for young children), fat-soluble vitamins, salt supplements in hot weather, azithromycin three times weekly for its anti-inflammatory effect in some patients.

Evening session: Repeat airway clearance and inhaled medications. For children on overnight G-tube feeds, the pump is set up at bedtime.

School accommodations are legal rights under Section 504 and IDEA. Children with CF commonly need: unrestricted bathroom access (for enzyme timing and gastrointestinal symptoms), permission to carry water and snacks, a private space to do treatments if a midday session is required, and flexibility on makeup work during hospitalizations.

Back to Table of Contents

CFTR Modulator Therapy — The Revolution

CFTR modulator drugs are small molecules that target the underlying protein defect in CF rather than just treating its consequences. Their development is one of the most significant advances in the history of genetic disease treatment.

Ivacaftor (Kalydeco), approved 2012: The first modulator, ivacaftor is a CFTR potentiator — it holds the CFTR channel open longer so more chloride can flow through. It works for gating mutations (class III), where the protein reaches the cell surface but opens too infrequently. The G551D mutation is the most common gating mutation, present in about 4–5% of CF patients. Ivacaftor produced dramatic improvements in FEV1 (+10–12 percentage points), sweat chloride, and quality of life. It is now approved for patients age 4 months and older with eligible mutations.

Lumacaftor/ivacaftor (Orkambi), approved 2015: Lumacaftor is a CFTR corrector — it helps the misfolded ΔF508 protein fold correctly and reach the cell surface, where ivacaftor can then potentiate it. This combination was the first therapy for the 70% of CF patients who carry two copies of ΔF508. Benefits were meaningful but modest (+2–3 percentage points FEV1), limited by the fact that lumacaftor also induces metabolism of ivacaftor.

Tezacaftor/ivacaftor (Symdeko), approved 2018: An improved corrector combination with better tolerability than Orkambi and modest additional benefit over lumacaftor/ivacaftor alone.

Elexacaftor/tezacaftor/ivacaftor (Trikafta), approved 2019: Trikafta represents the true breakthrough. It combines elexacaftor (a next-generation corrector that binds a different site on the ΔF508 protein than tezacaftor) with tezacaftor and ivacaftor in a triple-combination approach. The results were transformative in trials: FEV1 improved by an average of +14 percentage points, sweat chloride normalized in many patients, pulmonary exacerbations fell by 63%, and quality of life scores improved dramatically.

Trikafta is approved for patients age 2 and older who carry at least one copy of the ΔF508 mutation, making approximately 90% of all CF patients in the United States eligible. Children as young as 2 receive an age-appropriate granule formulation. For children starting Trikafta before significant lung damage has accumulated, projected lifespan approaches near-normal. Real-world data confirm that children on Trikafta who maintain FEV1 above 90% predicted have outcomes approaching those of the general population.

These drugs are not a cure — they require daily lifelong adherence and do not reverse existing lung damage — but they have so fundamentally changed the trajectory of CF that many pediatric CF specialists are now counseling families with a realistically optimistic outlook for children who start Trikafta early.

Back to Table of Contents

CF and Child Development

CF affects every dimension of a child's daily life, and understanding these impacts helps families and schools support children effectively.

School absenteeism: Children with CF miss more school than peers due to pulmonary exacerbations requiring hospitalization (average 1–2 weeks per admission), outpatient clinic appointments (typically quarterly), and treatment time. A hospitalization mid-semester can mean 2–3 weeks of missed school. Most families develop close relationships with their child's school to plan makeup work in advance.

Physical activity: Exercise is beneficial in CF and is actively encouraged. It promotes airway clearance, maintains muscle mass, improves cardiovascular fitness, and enhances quality of life. Children with CF should participate in physical education and sports. They may need extra water and salt, and they may need to take enzymes before strenuous activity if it coincides with eating. Mild exercise intolerance compared to peers is common before CFTR modulators; most Trikafta-treated children exercise without meaningful restriction.

Disclosing CF to peers and teachers: This is a deeply personal decision families make at different times. Many children do not want to be singled out, while others find that teachers who understand CF are better equipped to support them. Common accommodations disclosed include why a child carries enzyme capsules, why they use the restroom more frequently, or why they miss school during exacerbations.

Mental health: Rates of anxiety and depression are 2–3 times higher in children with CF compared to the general pediatric population, and rates in parents of children with CF are similarly elevated. The CF Foundation's TIDES study established this clearly. CF care centers routinely incorporate mental health screening and access to psychological support. Symptoms to watch for in children include school refusal, social withdrawal, refusing treatments, and persistent sadness or worry.

CF Foundation resources: The Cystic Fibrosis Foundation (cff.org) provides disease education, care center accreditation, peer mentorship programs, financial assistance programs for medications and care costs, and camps specifically for children with CF where social isolation is dramatically reduced.

Back to Table of Contents

Complications in Children

Meconium ileus: Approximately 10–15% of newborns with CF are born with meconium ileus, a blockage of the small intestine caused by abnormally thick meconium (the first stool). It is almost exclusively a CF complication and may be the presenting sign before newborn screening results return. Meconium ileus requires either a Gastrografin enema to loosen the plug or surgical intervention if the bowel is perforated or ischemic. Meconium ileus does not predict more severe CF lung disease.

Distal intestinal obstruction syndrome (DIOS): The CF equivalent of meconium ileus in older children and adults. Inspissated (dried, impacted) intestinal contents cause partial or complete bowel obstruction in the distal small intestine and cecum, presenting as cramping right lower quadrant pain and constipation. Managed with osmotic laxatives, Gastrografin, or IV hydration. Adequate enzyme dosing and hydration prevent recurrence.

Nasal polyps: Thick sinonasal secretions cause nasal polyps in 6–48% of CF patients, often beginning in childhood. Polyps cause nasal obstruction, impaired breathing, and recurrent sinusitis. They are managed with intranasal corticosteroids and may require endoscopic sinus surgery. CFTR modulators have reduced their severity.

CF-related liver disease: Thick bile causes focal biliary cirrhosis in about 25% of CF patients, though clinically significant portal hypertension or liver failure is less common (approximately 5%). It is most likely to progress during puberty. Liver function tests and liver ultrasound are monitored annually. Ursodeoxycholic acid is used to improve bile flow, though evidence for long-term benefit is limited. Severe liver disease can ultimately require transplant.

Bone disease: Vitamin D deficiency, malabsorption, chronic inflammation, steroid use, and reduced physical activity all contribute to lower bone mineral density in CF. DXA scan (bone density) monitoring begins at age 8–10. Vitamin D and calcium supplementation, weight-bearing exercise, and CFTR modulators all help protect bone health.

Male infertility: Approximately 97–98% of males with CF are infertile due to congenital bilateral absence of the vas deferens (CBAVD), caused by a CF-specific structural defect that prevents the vas deferens from developing. Testosterone production and sexual function are normal. Sperm are produced normally and can be retrieved for assisted reproductive technologies (intracytoplasmic sperm injection, ICSI). This should be discussed with adolescent males as they approach puberty so they understand their future options.

Female fertility: Females with CF have reduced fertility due to abnormally thick cervical mucus, but are not infertile. With improved health status from CFTR modulators, more women with CF are pursuing pregnancy. Pregnancy in CF requires specialized preconception counseling and high-risk obstetric care.

Back to Table of Contents

Transition to Adult Care

The transition from pediatric to adult CF care is a critical and vulnerable period. It typically occurs around age 18, though some centers begin the process at 16. The CF Foundation has developed formal transition guidelines recognizing that this handoff, if handled poorly, is associated with worsening lung function, hospitalizations, and loss of follow-up.

In the pediatric CF model, parents manage most of the disease burden — filling prescriptions, scheduling appointments, communicating with the care team, and supervising treatments. In adult CF care, the patient is the primary manager. The transition process therefore involves gradual transfer of responsibility: beginning around age 12–14, children are increasingly expected to communicate directly with the care team during clinic visits, know their own medications and doses, and independently perform treatments when hospitalized.

Key areas addressed in transition programs include:

Many pediatric CF centers use structured transition readiness assessments (such as the CF-specific TRAQ tool) to track skill development and identify gaps before the formal handoff. A joint pediatric-adult clinic visit, where the patient meets the adult team before transferring, significantly improves transition outcomes.

Back to Table of Contents

Prognosis and Outlook

The trajectory of CF prognosis is one of the most dramatic improvement stories in modern medicine. In the 1950s, most children with CF died in infancy. By 1985, median survival had reached the late teens. By 2010, median survival approached 40 years. With the introduction of CFTR modulators and particularly Trikafta, the projected median survival for children born today with eligible mutations exceeds 70 years, approaching the normal lifespan of the general population.

The Cystic Fibrosis Foundation Patient Registry data show that since Trikafta's 2019 approval, FEV1 values have risen across the CF population, hospitalization rates have fallen, and pulmonary exacerbation rates have dropped by more than 60%. The lung function in many Trikafta-treated children starting therapy before significant damage accumulates remains in or near the normal range throughout childhood and adolescence — a scenario unimaginable twenty years ago.

For the approximately 10% of CF patients who carry mutations not responsive to any currently available modulator (primarily nonsense mutations causing premature stop codons), lung disease continues to progress on its previous trajectory. Research into read-through agents, gene editing, and gene therapy is actively ongoing for these patients. Lung transplantation remains an option for patients with end-stage lung disease regardless of mutation class — it replaces the damaged lungs but does not correct CF in other organs.

The prognosis for CF-related complications has also improved. CFRD can be managed effectively with insulin. Liver disease rarely progresses to transplant-requiring cirrhosis. Bone disease is addressable. Male infertility, while not curable, is navigable through assisted reproduction. The mental health burden is real but responsive to appropriate support.

Parents of a newly diagnosed child with CF today are counseling a different disease than parents heard about even a decade ago. The honest message is this: CF is still a serious, life-altering condition that requires daily treatment and medical surveillance. But for children who start CFTR modulator therapy early, who maintain good adherence, and who are followed by an experienced CF care center, the realistic expectation is a full life — college, career, relationships, family — that was not achievable for prior generations.

Back to Table of Contents

Key Research Papers

The following studies have shaped current understanding and treatment of cystic fibrosis in children:

  1. Middleton PG, Mall MA, Drevinek P, et al. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809–1819. PMID 31597044
  2. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010;363(21):1991–2003. PMID 21083385
  3. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220–231. PMID 25981758
  4. Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–2531. PMID 27751247
  5. Farrell PM, White TB, Ren CL, et al. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017;181S:S4–S15. PMID 28129811
  6. Borowitz D, Robinson KA, Rosenfeld M, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr. 2009;155(6 Suppl):S73–93. PMID 19914445
  7. Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis–related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation. Diabetes Care. 2010;33(12):2697–2708. PMID 21115772
  8. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–1672. PMID 22047557
  9. Sawicki GS, Sellers DE, Robinson WM. High school- and college-age adults with cystic fibrosis: transition to self-management. J Adolesc Health. 2008;42(3):223–230. PMID 18295128
  10. Quittner AL, Goldbeck L, Abbott J, et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of the International Depression Epidemiological Study across nine countries. Thorax. 2014;69(12):1090–1097. PMID 25246435
  11. West NE, Mogayzel PJ. Transitions in Health Care: What Can We Learn from Our Experience with Cystic Fibrosis? Pediatr Clin North Am. 2016;63(5):887–897. PMID 27565293
  12. Schwarzenberg SJ, Hempstead SE, McDonald CM, et al. Enteral tube feeding for individuals with cystic fibrosis: Cystic Fibrosis Foundation evidence-informed guidelines. J Cyst Fibros. 2016;15(6):724–735. PMID 27599607

Search PubMed for additional research:

Back to Table of Contents

Connections